Search Results - Roberto Ravasio

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy by Roberto Ravasio, Silvia Ripoli

    Published in AboutOpen (2023-05-01)
    Get full text
    Article


  2. 2

    Title not available by Nicola Petrosillo, Roberto Ravasio

    Get full text
    Article


  3. 3

    Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy by Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio

    Published in AboutOpen (2024-06-01)
    Get full text
    Article


  4. 4

    Title not available by Roberto Ravasio, Giuseppe Nicolò, Marco Vaggi

    Get full text
    Article


  5. 5

    Analisi di budget impact del biosimilare di etanercept: lo scenario italiano by Roberto Ravasio, Giampiero Girolomoni, Roberto Gorla

    Get full text
    Article


  6. 6

    Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy by Roberto Ravasio, Raffaella Viti, Antonio Saverio Roscini

    Published in AboutOpen (2023-01-01)
    Get full text
    Article


  7. 7

    Title not available by Paola Saturnino, Maria Pia Mannelli, Roberto Ravasio

    Get full text
    Article


  8. 8

    Budget impact analysis of ticagrelor for preventive treatment of patients with acute coronary syndromes by Gian Piero Perna, Roberto Ravasio, Antonio Ricciardelli

    Get full text
    Article


  9. 9

    The cost of antibiotic therapy and antibiotic resistance for complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) in Italy by Paola Saturnino, Maria Pia Mannelli, Roberto Ravasio

    Get full text
    Article


  10. 10

    Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model by Roberto Ravasio, Andrea Marcellusi, Luca De Nicola

    Get full text
    Article


  11. 11

    The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study by Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

    Get full text
    Article


  12. 12

    Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations by Adolfo Favaretto, Francesco Grossi, Alessandro Morabito, Roberto Ravasio

    Get full text
    Article


  13. 13

    Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy by Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

    Get full text
    Article


  14. 14

    Title not available by Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo, Serena Losi

    Get full text
    Article


  15. 15

    Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis by Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio

    Get full text
    Article


  16. 16

    Cost analysis of residual viremia detected by two real-time PCR assays for response-guided (dual or triple) therapy of HCV genotype 1 infection by Alessio Aghemo, Giovanna Lunghi, Roberto Ravasio, Erminio Torresani, Matteo Dionisi, Davide Paolini, Massimo Colombo

    Get full text
    Article


  17. 17

    Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy by Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi

    Get full text
    Article


  18. 18

    Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy by Patrizio Armeni, Elena Compagnucci, Gionata Fiorino, Vincenzo Lolli, Grazia Mazzone, Ambrogio Orlando, Mariabeatrice Principi, Roberto Ravasio, Fernando Rizzello, Edoardo Vincenzo Savarino, Francesca Tombari

    Published in AboutOpen (2024-03-01)
    Get full text
    Article


  19. 19

    Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy by Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti, Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone

    Published in Dermatology Practical & Conceptual (2025-01-01)
    Get full text
    Article


  20. 20

    Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion by Rani Pallavi, Elena Gatti, Tiphanie Durfort, Massimo Stendardo, Roberto Ravasio, Tommaso Leonardi, Paolo Falvo, Bruno Achutti Duso, Simona Punzi, Aobuli Xieraili, Andrea Polazzi, Doriana Verrelli, Deborah Trastulli, Simona Ronzoni, Simone Frascolla, Giulia Perticari, Mohamed Elgendy, Mario Varasi, Emanuela Colombo, Marco Giorgio, Luisa Lanfrancone, Saverio Minucci, Luca Mazzarella, Pier Giuseppe Pelicci

    Published in Nature Communications (2024-01-01)
    Get full text
    Article


Search Tools: